The metastatic potential of breast cancer cells is correlated with the molecular subtype: luminal tumor subtypes exhibit a reduced malignant progression rate and a more favorable response to therapy than the HER2-overexpressing and triple-negative subtypes of breast cancer.56 The gene discussed is ERBB2; the disease is breast cancer.